Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor
| Autor: | Irene M. Lang, Gerhard Kreiner, Betül Akca, Rudolf Berger, Thomas Neunteufl, Jolanta M. Siller-Matula, Gerald Maurer, Georg Delle-Karth |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Blood Platelets
Male Ticagrelor medicine.medical_specialty Acute coronary syndrome Adenosine Prasugrel Platelet Aggregation 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Risk Factors Interquartile range Internal medicine medicine Humans Prospective Studies 030212 general & internal medicine Platelet activation Acute Coronary Syndrome Aged Prasugrel Hydrochloride business.industry Hematology General Medicine Middle Aged Platelet Activation medicine.disease Adenosine Diphosphate Treatment Outcome Pharmacodynamics Cardiology Platelet aggregation inhibitor Female business Biomarkers Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | Platelets. 27:373-377 |
| ISSN: | 1369-1635 0953-7104 |
| Popis: | The aim of this study was to evaluate the distribution of platelet reactivity values in patients treated with prasugrel and ticagrelor. This prospective observational study enrolled 200 patients treated with prasugrel or ticagrelor. Platelet aggregation was determined by multiple electrode aggregometry after stimulation with adenosine diphosphate (ADP) in the maintenance phase of treatment with prasugrel or ticagrelor. Only 3% of patients in the prasugrel group and 2% of study participants in the ticagrelor group had high on treatment platelet reactivity (HTPR). The majority of patients displayed low on treatment platelet reactivity (LTPR; prasugrel: 69%; ticagrelor: 64%). The pharmacodynamic effect was similar in patients treated with prasugrel and ticagrelor: the median level of ADP-induced platelet aggregation was 15U (interquartile range IQR 9-21U) under prasugrel treatment and 17U (IQR 8-24U) under ticagrelor treatment (p=0.370). In conclusion, our study suggests that there is some degree of variability in ADP-induced platelet aggregation under treatment with prasugrel and ticagrelor. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|